A PHASE 3, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF GTX-102 IN PEDIATRIC SUBJECTS WITH ANGELMAN SYNDROME

Registry ID

GTX-102-CL301

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ULTRAGENYX PHARMACEUTICAL INC

Start date

2026-01-30

Last update

2024-11-19

Conditions

• ANGELMAN SYNDROME (AS)

Related clinical trials

• PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF ION582 IN CHILDREN AND ADULTS WITH ANGELMAN SYNDROME
• A LONG-TERM EXTENSION TRIAL INVESTIGATING THE SAFETY AND EFFICACY OF GTX-102 IN PATIENTS WITH ANGELMAN SYNDROME

View on source registry